Skip to main content

Table 6 Incidence of hypoglycemia in patients with insulin dose reduction

From: Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus

Type of insulin regimen

Total (N = 3)

Premixed (N = 1)

Long-acting (N = 1)

Premixed + rapid- or short-acting (N = 1)

Long-acting + rapid- or short-acting (N = 0)

Placebo

 Before first dose reduction

  Cumulative exposure (subject-year)

0.72

0.23

0.26

0.23

–

  Number of events

16

14

0

2

–

  Incidence per subject-year exposure

22.31

60.88

0

8.70

–

 After first dose reduction

  Cumulative exposure (subject-year)

0.18

0.08

0.03

0.08

–

  Number of events

5

4

0

1

–

  Incidence per subject-year exposure

27.26

52.18

0

13.04

–

Type of insulin regimen

Total (N = 14)

Premixed (N = 4)

Long-acting (N = 5)

Premixed + rapid- or short-acting (N = 0)

Long-acting + rapid- or short-acting (N = 5)

Canagliflozin 100 mg

 Before first dose reduction

  Cumulative exposure (subject-year)

1.54

0.42

0.59

–

0.53

  Number of events

72

22

20

–

30

  Incidence per subject-year exposure

46.88

52.87

33.98

–

56.48

 After first dose reduction

  Cumulative exposure (subject-year)

2.55

0.64

0.93

–

0.98

  Number of events

62

17

18

–

27

  Incidence per subject-year exposure

24.27

26.65

19.28

–

27.47

  1. Hypoglycemia in the follow-up period was excluded. Incidence per subject-year exposure: events/total exposure (subject-year)
  2. N number of patients